Welcome to our dedicated page for Hutchmed (China) SEC filings (Ticker: HCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HUTCHMED (China) Limited filings document a foreign private issuer with American depositary shares linked to its ordinary-share capital. Form 6-K submissions furnish press releases, annual report materials, shareholder-meeting documents, total voting-rights notices, and governance disclosures for the company’s Nasdaq, AIM and HKEX-listed securities.
The filing record covers HUTCHMED’s targeted therapy and immunotherapy business, China regulatory updates, oncology and immunology pipeline disclosures, licensed product matters, and annual reporting. Other recurring filing subjects include AGM notices and proxy materials, voting instructions for American depositary share holders, long-term incentive plan award vesting, and capital-structure details for ordinary shares, depositary interests and ADSs.
HUTCHMED (China) Limited reports that China’s National Medical Products Administration has granted conditional approval for ORPATHYS® (savolitinib) to treat locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with MET amplification after at least two prior systemic treatments.
ORPATHYS® is described as the first selective MET inhibitor approved in China for this MET‑amplified gastric cancer population, which the company cites as an estimated 4–6% of gastric cancer cases, or about 18,000 patients annually. The approval is based on a pivotal Phase II study that met its primary endpoint, with an independently reviewed objective response rate of 32.3% and a disease control rate of 63.1% as of the October 8, 2025 data cut‑off.
HUTCHMED (China) Limited has scheduled the announcement of its interim results for the six months ended June 30, 2026 for Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time, 12:00 noon British Summer Time and 7:00 pm Hong Kong Time. Management will host two webcast presentations with Q&A: an English webcast on July 30, 2026 at 8:00 am EDT, 1:00 pm BST and 8:00 pm HKT, and a Putonghua webcast on July 31, 2026 at 8:30 am HKT (1:30 am BST and 8:30 pm EDT on July 30, 2026). The live and replay webcasts and presentation materials will be accessible via the company website. HUTCHMED is described as an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases, with three medicines marketed in China and one also approved in the US, Europe and Japan.
HUTCHMED (China) Limited filed a blocklisting six monthly return covering its share option schemes for the period from December 29, 2025 to June 28, 2026. The company reports activity under both its 2015 and 2026 HUTCHMED Share Option Schemes.
Under the 2015 scheme, 7,500 ordinary shares of US$0.1 each were issued during the period, leaving 45,768,368 shares available but not yet issued or allotted at the period end. The 2026 scheme was increased by 43,616,756 ordinary shares, all of which remain unissued at the end of the period.
The filing also notes that a total of 872,335,120 ordinary shares of US$0.1 each were in issue at the end of the period, providing context for the scale of these share option arrangements.
HUTCHMED (China) Limited reported pivotal Phase II results for its FGFR inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions or rearrangements. In this single-arm, multi-center trial across 53 sites in China, all patients had received prior systemic therapy, including chemotherapy and, for most, immunotherapy.
The study met its primary endpoint with an Independent Review Committee–assessed objective response rate of 42.5%, and a disease control rate of 83.9%. Responses occurred quickly, with a median time to response of 1.4 months, and showed durability, with median duration of response and progression-free survival both at 6.9 months. Median overall survival reached 16.6 months, suggesting meaningful benefit in a difficult-to-treat population.
Fanregratinib showed a manageable safety profile typical of selective FGFR inhibitors. Grade 3 or higher drug-related adverse events occurred in 48.3% of patients, mainly liver enzyme elevations and palmar-plantar erythrodysesthesia, but treatment discontinuations due to drug-related events were limited to 2.2%, and no treatment-related deaths were reported. Supported by these data, a New Drug Application for fanregratinib in this indication has been accepted and granted priority review by China’s National Medical Products Administration.
HUTCHMED reports detailed Phase III ESLIM-02 results for its oral Syk inhibitor sovleplenib in adults with warm antibody autoimmune hemolytic anemia (wAIHA) in China. The study met its primary endpoint, with a durable hemoglobin response in 66% of sovleplenib patients versus 15% on placebo between weeks 5–24.
Overall response rate, defined by meaningful hemoglobin improvement without rescue therapy, was 70% for sovleplenib versus 22% for placebo, and use of rescue therapy and blood transfusions was markedly lower in the treatment arm. Median time to response was shorter and duration of response longer with sovleplenib, and subgroup data in patients previously treated with rituximab remained favorable.
Sovleplenib showed a favorable safety profile, with Grade ≥3 treatment-emergent adverse events in 43% of patients versus 59% on placebo and no treatment-related deaths or discontinuations in the sovleplenib arm. Supported by ESLIM-02, a New Drug Application for sovleplenib in wAIHA has been accepted and granted priority review, following earlier Breakthrough Therapy Designation in China.
HUTCHMED (China) Limited has applied to the London Stock Exchange for a block admission of 43,616,756 ordinary shares, each with a par value of US$0.10, to be admitted to trading on AIM in connection with its 2026 Share Option Scheme. Admission is expected to become effective on June 11, 2026. These shares may be issued over time upon exercise of options granted under the scheme and will rank equally with existing ordinary shares. Following admission, the Company’s total issued share capital remains 872,335,120 ordinary shares, each carrying one voting right, with no shares held in treasury. An existing block admission of 45,768,368 ordinary shares relating to a 2015 share option scheme also remains in effect.
HUTCHMED (China) Limited is sharing a broad set of oncology clinical data at the 2026 ASCO Annual Meeting in Chicago. The centerpiece is a pivotal Phase II registration study of savolitinib in MET-amplified gastric or gastroesophageal junction cancer in China.
The savolitinib study met its primary endpoint, with an Independent Review Committee–assessed objective response rate of 32.3% as of October 8, 2025, exceeding a pre-specified efficacy threshold. Disease control rate was 63.1%, median time to response 1.4 months, duration of response 9.7 months, and progression-free survival 4.0 months. These data supported a New Drug Application in China that was accepted and granted priority review.
The company will also present further analyses from its fruquintinib FRESCO, FRESCO-2, FRUSICA-1 and FRUSICA-2 studies, plus numerous investigator-initiated studies of fruquintinib and surufatinib across colorectal, gastric, renal, gynecologic, hepatobiliary, pancreatic, lung and other tumor types, highlighting the breadth of its clinical development program.
HUTCHMED (China) Limited reports that China’s NMPA has approved ELUNATE (fruquintinib) plus TYVYT (sintilimab injection) for patients with locally advanced or metastatic renal cell carcinoma after VEGFR-TKI therapy and without prior PD-1/PD-L1 treatment in first line.
The approval is based on the Phase III FRUSICA-2 study, where the combination reduced the risk of disease progression or death by 63% and achieved a median progression free survival of 22.2 months versus 6.9 months on axitinib or everolimus. Objective response rate was 60.5% compared with 24.3%, and median duration of response reached 23.7 months versus 11.3 months. Safety was consistent with known profiles of each drug.
HUTCHMED (China) Limited reports that China’s NMPA has approved ELUNATE (fruquintinib) plus TYVYT (sintilimab injection) for patients with locally advanced or metastatic renal cell carcinoma after VEGFR-TKI therapy and without prior PD-1/PD-L1 treatment in first line.
The approval is based on the Phase III FRUSICA-2 study, where the combination reduced the risk of disease progression or death by 63% and achieved a median progression free survival of 22.2 months versus 6.9 months on axitinib or everolimus. Objective response rate was 60.5% compared with 24.3%, and median duration of response reached 23.7 months versus 11.3 months. Safety was consistent with known profiles of each drug.
HUTCHMED (China) Ltd director and acting CEO/CFO Cheng Chig Fung reported performance-based equity allocations under the company’s Long Term Incentive Plan. On May 20, 2026, 30,157 ordinary shares from 2024 LTIP awards and 26,307 ordinary shares from 2025 LTIP awards were allocated at a purchase price of zero. The shares are held indirectly by an LTIP trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, subject to award terms. These are compensation-related restructurings rather than open-market trades.
HUTCHMED (China) Ltd director and acting CEO/CFO Cheng Chig Fung reported performance-based equity allocations under the company’s Long Term Incentive Plan. On May 20, 2026, 30,157 ordinary shares from 2024 LTIP awards and 26,307 ordinary shares from 2025 LTIP awards were allocated at a purchase price of zero. The shares are held indirectly by an LTIP trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, subject to award terms. These are compensation-related restructurings rather than open-market trades.
HUTCHMED (China) Ltd Group General Counsel Charles George Rupert Nixon reported compensation-related allocations under the company’s Long Term Incentive Plan. On the reported date, 7,445 ordinary shares from awards granted on August 5, 2024 and 7,644 ordinary shares from awards granted on June 9, 2025 were allocated at a purchase price of zero.
The shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, respectively, subject to the award terms. These are indirect holdings and there were no open-market buys or sells.
HUTCHMED (China) Ltd Group General Counsel Charles George Rupert Nixon reported compensation-related allocations under the company’s Long Term Incentive Plan. On the reported date, 7,445 ordinary shares from awards granted on August 5, 2024 and 7,644 ordinary shares from awards granted on June 9, 2025 were allocated at a purchase price of zero.
The shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, respectively, subject to the award terms. These are indirect holdings and there were no open-market buys or sells.